Clinical Trial Update: A Study of the Effects of CY6463 in Participants With Alzheimer's Disease With Vascular Pathology [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating CY6463 in participants with Alzheimer's disease with vascular pathology has been terminated, and results were posted on 2024-10-30.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• CY6463

Snippet

Sponsor: Tisento Therapeutics | Conditions: Alzheimer's Disease With Vascular Pathology | Phase 2 | Status: TERMINATED | Results posted: 2024-10-30